文献速递放疗物理与技术姑息放疗与转移瘤

超一亿商业保险人群中光子和质子放疗的使用趋势

Photon and Proton Radiation Therapy Utilization in a Population of More Than 100 Million Commercially Insured Patients.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-08-02

该回顾性分析基于OptumLabs理赔数据库,描述了2002至2012年间超过1亿参保人中放疗使用变化,共474533例接受放疗。结果显示IMRT使用大幅增长(尤其前列腺癌从3.5%至64.0%),质子束放疗整体使用率仍很低(2012年0.6%),儿童中从0.3%升至9.7%。

要点

  • IMRT使用增长最显著,前列腺癌从3.5%升至64.0%。
  • 质子束放疗整体使用率低,2012年仅0.6%,儿童中升至9.7%。
  • 先进技术(SBRT和PBRT)使用率不足2%,远低于IMRT的22%。

核心结论

  • 质子束放疗使用率仍很低,对整体放疗使用影响小,IMRT是最大变化尤其是前列腺癌。

研究设计与样本

  • 回顾性分析OptumLabs Data Warehouse理赔数据库,覆盖超过1亿美国参保人,评估2002至2012年放疗使用特征。

主要发现

  • 2002至2012年共474533例患者接受放疗。
  • 2002年3DCRT、2DRT/近距离、IMRT、SBRT、PBRT占比分别为34.5%、63.4%、2.1%、0.0%、0.1%;2012年分别为40.4%、36.0%、21.9%、1.1%、0.6%。
  • 前列腺癌IMRT使用从3.5%增至64.0%,非前列腺癌成人从1.7%增至16.4%。
  • 儿童PBRT从0.3%增至9.7%,前列腺癌PBRT从0.0%增至2.6%。
  • 所有患者中先进技术(SBRT和PBRT)使用率<2%,IMRT为22%。

临床怎么用

  • 了解质子束放疗在商业保险人群中整体使用率低,对放疗总支出影响有限。

局限性

  • 基于理赔数据库的回顾性分析,可能受编码和参保人群特征影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To characterize the changes in the use of radiation therapy (RT), specifically proton beam radiation therapy (PBRT), among adult and pediatric patients over a 11-year period in a very large population of insured patients. METHODS AND MATERIALS: We conducted a retrospective analysis of the OptumLabs Data Warehouse claims database of more than 100 million insured US enrollees. Descriptive analyses were undertaken to evaluate the characteristics of patients receiving RT from 2002 to 2012. RESULTS: There were 474,533 patients treated with RT from 2002 to 2012. The percentage of patients treated with 3-dimensional conformal radiation therapy, 2-dimensional RT/brachytherapy, intensity modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), and PBRT was 34.5%, 63.4%, 2.1%, 0.0%, and 0.1% and 40.4%, 36.0%, 21.9%, 1.1%, and 0.6% in 2002 and 2012, respectively. The greatest increase in utilization was of IMRT for prostate cancer, growing from 3.5% to 64.0%. For non-prostate cancer adults, IMRT use grew from 1.7% to 16.4%. For children, PBRT utilization increased from 0.3% to 9.7%. For prostate cancer patients, PBRT increased from 0.0% to 2.6%. For all patients, advanced technology (SBRT and PBRT) use was very low at <2%, versus 22% for IMRT. CONCLUSIONS: This is the largest and most geographically diverse description of RT utilization. Proton beam RT utilization remains very low and has had little impact on overall RT utilization compared with IMRT. The largest shift has occurred in IMRT for prostate cancer. Our findings indicate that overall utilization of proton therapy has been low and that its use has likely had little impact on national expenditures on cancer care in the current environment.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Waddle MR, Sio TT, Van Houten HK, et al. Photon and Proton Radiation Therapy Utilization in a Population of More Than 100 Million Commercially Insured Patients. Int J Radiat Oncol Biol Phys. 2017. PMID: 28939229. doi:10.1016/j.ijrobp.2017.07.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。